Sunday, February 21, 2016

Relapse Prevention Medications in Community Treatment for Young Adults with Opioid Addiction

BACKGROUND:
Despite the well-known effectiveness and widespread use of relapse prevention medications such as extended release naltrexone (XR-NTX) and buprenorphine for opioid addiction in adults, less is known about their use in younger populations.

METHODS:
This was a naturalistic study using retrospective chart review of N = 56 serial admissions into a specialty community treatment program that featured the use of relapse prevention medications for young adults with opioid use disorders (19-26). Treatment outcomes over 24 weeks included retention, and weekly opioid negative urine tests.

RESULTS:
Patients were mean age 23.1, 70% male, 86% Caucasian, 82% with history of injection heroin use, and treated with either buprenorphine (77%) or XR-NTX (23%). The mean number of XR-NTX doses received was 4.1. Retention was approximately 65% at 12 weeks and 40% at 24 weeks, and rates of opioid negative urine were 50% at 12 weeks and 39% at 24 weeks, with missing samples imputed as positive. There were no statistically significant differences in retention (t = 1.87, p = .06) or in rates of weekly opioid negative urine tests (t = 1.96, p = .06) between medication groups, over the course of 24 weeks. The XR-NTX group had higher rates of weekly negative urine drug tests for other non-opioid substances (t = 2.83; p < .05) compared to the buprenorphine group. Males were retained in treatment longer and had higher rates of opioid negative weeks compared to females.

CONCLUSIONS:
Our results suggest that relapse prevention medications including both buprenorphine and XR-NTX can be effectively incorporated into standard community treatment for opioid addiction in young adults with good results. Specialty programming focused on opioid addiction in young adults may provide a promising model for further treatment development.

Purchase full article at:   http://goo.gl/n9kEsy

By:    Vo HT1Robbins E1Westwood M1Lezama D1Fishman M1,2.
  • 1 Maryland Treatment Centers , Baltimore , MD , USA.
  • 2 Johns Hopkins School of Medicine , Baltimore , MD , USA.
  •  2016 Jan 28:0 



No comments:

Post a Comment